Sobi CMO Leaves To Join GSK
This article was originally published in Scrip
Swedish Orphan Biovitrum AB (Sobi) has announced that its senior vice president of development and chief medical officer (CMO), Birgitte Volck, will be leaving the company to join GlaxoSmithKline as head of R&D rare diseases. Volck will work through a six month notice period before she leaves her position at Sobi.
Register for our free email digests: